You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

HEMABATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Hemabate, and what generic alternatives are available?

Hemabate is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in HEMABATE is carboprost tromethamine. There is one drug master file entry for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the carboprost tromethamine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Hemabate

A generic version of HEMABATE was approved as carboprost tromethamine by DR REDDYS on July 2nd, 2019.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for HEMABATE?
  • What are the global sales for HEMABATE?
  • What is Average Wholesale Price for HEMABATE?
Summary for HEMABATE
Drug patent expirations by year for HEMABATE
Drug Prices for HEMABATE

See drug prices for HEMABATE

Recent Clinical Trials for HEMABATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Northwestern UniversityEarly Phase 1
West China Second University HospitalPhase 4
Dongguan Maternity & Child Health HospitalN/A

See all HEMABATE clinical trials

Pharmacology for HEMABATE

US Patents and Regulatory Information for HEMABATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer HEMABATE carboprost tromethamine INJECTABLE;INJECTION 017989-001 Approved Prior to Jan 1, 1982 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for HEMABATE

See the table below for patents covering HEMABATE around the world.

Country Patent Number Title Estimated Expiration
U.S.S.R. 416939 ⤷  Sign Up
United Kingdom 1314291 ⤷  Sign Up
Spain 390709 ⤷  Sign Up
Poland 81615 ⤷  Sign Up
Norway 135935 ⤷  Sign Up
Finland 57582 ⤷  Sign Up
Argentina 193032 UN PROCEDIMIENTO PARA PRODUCIR DERIVADOS DEL ACIDO PROSTANOICO ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.